[1]
Devillier P,Roche N,Faisy C, Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clinical pharmacokinetics. 2008;
[PubMed PMID: 18336052]
Level 2 (mid-level) evidence
[3]
Van Cauwenberge P,Juniper EF, Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2000 Jun;
[PubMed PMID: 10848909]
Level 2 (mid-level) evidence
[4]
Ansotegui IJ,Bernstein JA,Canonica GW,Gonzalez-Diaz SN,Martin BL,Morais-Almeida M,Murrieta-Aguttes M,Sanchez Borges M, Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2022 May 13
[PubMed PMID: 35562767]
[5]
Iijima S,Kojo K,Takayama N,Hiragun M,Kan T,Hide M, Case of cholinergic urticaria accompanied by anaphylaxis. The Journal of dermatology. 2017 Nov
[PubMed PMID: 28665007]
Level 3 (low-level) evidence
[6]
Mahatme MS,Dakhale GN,Tadke K,Hiware SK,Dudhgaonkar SD,Wankhede S, Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Indian journal of pharmacology. 2016 Nov-Dec;
[PubMed PMID: 28066101]
Level 1 (high-level) evidence
[7]
Kawauchi H,Yanai K,Wang DY,Itahashi K,Okubo K, Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. International journal of molecular sciences. 2019 Jan 8;
[PubMed PMID: 30626077]
[8]
Orzechowski RF, Currie DS, Valancius CA. Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models. European journal of pharmacology. 2005 Jan 4:506(3):257-64
[PubMed PMID: 15627436]
Level 2 (mid-level) evidence
[9]
Canonica GW,Blaiss M, Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. The World Allergy Organization journal. 2011 Feb
[PubMed PMID: 23268457]
[10]
Meltzer EO,Rosario NA,Van Bever H,Lucio L, Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2021 Nov 2;
[PubMed PMID: 34727966]
[11]
Huang CZ,Jiang ZH,Wang J,Luo Y,Peng H, Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials. BMC pharmacology & toxicology. 2019 Nov 29
[PubMed PMID: 31783781]
Level 1 (high-level) evidence
[12]
Simpson K,Jarvis B, Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000 Feb;
[PubMed PMID: 10730552]
[13]
Cole S,Bagal S,El-Kattan A,Fenner K,Hay T,Kempshall S,Lunn G,Varma M,Stupple P,Speed W, Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration. Xenobiotica; the fate of foreign compounds in biological systems. 2012 Jan;
[PubMed PMID: 21970687]
[14]
Akamine Y,Miura M, An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert opinion on drug metabolism & toxicology. 2018 Apr
[PubMed PMID: 29635947]
Level 3 (low-level) evidence
[15]
Martinez JM,Khier S,Morita S,Rauch C,Fabre D, Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients. Journal of pharmacokinetics and pharmacodynamics. 2014 Apr
[PubMed PMID: 24633780]
[16]
Meltzer EO,Scheinmann P,Rosado Pinto JE,Bachert C,Hedlin G,Wahn U,Finn AF Jr,Ruuth E, Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2004 Jun;
[PubMed PMID: 15209959]
[17]
Bernstein JA,Lang DM,Khan DA,Craig T,Dreyfus D,Hsieh F,Sheikh J,Weldon D,Zuraw B,Bernstein DI,Blessing-Moore J,Cox L,Nicklas RA,Oppenheimer J,Portnoy JM,Randolph CR,Schuller DE,Spector SL,Tilles SA,Wallace D, The diagnosis and management of acute and chronic urticaria: 2014 update. The Journal of allergy and clinical immunology. 2014 May
[PubMed PMID: 24766875]
[18]
Nolin TD,Frye RF,Le P,Sadr H,Naud J,Leblond FA,Pichette V,Himmelfarb J, ESRD impairs nonrenal clearance of fexofenadine but not midazolam. Journal of the American Society of Nephrology : JASN. 2009 Oct;
[PubMed PMID: 19696225]
[19]
Murase JE,Heller MM,Butler DC, Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. Journal of the American Academy of Dermatology. 2014 Mar
[PubMed PMID: 24528911]
[20]
Andersson NW,Torp-Pedersen C,Andersen JT, Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes. JAMA pediatrics. 2020 Aug 1;
[PubMed PMID: 32478810]
[21]
Kar S,Krishnan A,Preetha K,Mohankar A, A review of antihistamines used during pregnancy. Journal of pharmacology & pharmacotherapeutics. 2012 Apr
[PubMed PMID: 22629082]
[22]
Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT, British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2015 Mar:45(3):547-65. doi: 10.1111/cea.12494. Epub
[PubMed PMID: 25711134]
[23]
Andersson NW,Poulsen HE,Andersen JT, Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study. The journal of allergy and clinical immunology. In practice. 2020 May
[PubMed PMID: 32142963]
[25]
Butler DC,Heller MM,Murase JE, Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. Journal of the American Academy of Dermatology. 2014 Mar
[PubMed PMID: 24528912]
[26]
Compalati E,Baena-Cagnani R,Penagos M,Badellino H,Braido F,Gómez RM,Canonica GW,Baena-Cagnani CE, Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International archives of allergy and immunology. 2011;
[PubMed PMID: 21969990]
Level 1 (high-level) evidence
[27]
Mancano MA, ISMP Adverse Drug Reactions: Propofol-Related Infusion Syndrome (PRIS){sup}1,2{/sup}; Ivermectin-Induced Stevens-Johnson Syndrome; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Fexofenadine; Memantine-Related Drug Eruption. Hospital pharmacy. 2018 Jul
[PubMed PMID: 30038437]
[28]
Bailey DG, Fruit juice inhibition of uptake transport: a new type of food-drug interaction. British journal of clinical pharmacology. 2010 Nov
[PubMed PMID: 21039758]
[29]
Misaka S,Ono Y,Taudte RV,Hoier E,Ogata H,Ono T,König J,Watanabe H,Fromm MF,Shimomura K, Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers. Clinical pharmacology and therapeutics. 2022 Sep;
[PubMed PMID: 35678032]
[30]
Di Mizio G,Marcianò G,Palleria C,Muraca L,Rania V,Roberti R,Spaziano G,Piscopo A,Ciconte V,Di Nunno N,Esposito M,Viola P,Pisani D,De Sarro G,Raffi M,Piras A,Chiarella G,Gallelli L, Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications. International journal of environmental research and public health. 2021 Dec 8;
[PubMed PMID: 34948545]
[31]
Sarfraz N,Okuampa D,Hansen H,Alvarez M,Cornett EM,Kakazu J,Kaye AM,Kaye AD, pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Health psychology research. 2022
[PubMed PMID: 35774905]
[32]
Duran I,Carles J,Bulat I,Hellemans P,Mitselos A,Ward P,Jiao J,Armas D,Chien C, Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. Clinical pharmacokinetics. 2020 Sep
[PubMed PMID: 32338345]
[34]
Paśko P,Rodacki T,Domagała-Rodacka R,Palimonka K,Marcinkowska M,Owczarek D, Second generation H1 - antihistamines interaction with food and alcohol-A systematic review. Biomedicine
[PubMed PMID: 28622592]
Level 1 (high-level) evidence
[35]
Gonzalez-Estrada A, Geraci SA. Allergy Medications During Pregnancy. The American journal of the medical sciences. 2016 Sep:352(3):326-31. doi: 10.1016/j.amjms.2016.05.030. Epub 2016 Jun 3
[PubMed PMID: 27650241]
[36]
van Wegberg AMJ,MacDonald A,Ahring K,Bélanger-Quintana A,Blau N,Bosch AM,Burlina A,Campistol J,Feillet F,Giżewska M,Huijbregts SC,Kearney S,Leuzzi V,Maillot F,Muntau AC,van Rijn M,Trefz F,Walter JH,van Spronsen FJ, The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet journal of rare diseases. 2017 Oct 12;
[PubMed PMID: 29025426]
[37]
Pratt CM,Mason J,Russell T,Reynolds R,Ahlbrandt R, Cardiovascular safety of fexofenadine HCl. The American journal of cardiology. 1999 May 15
[PubMed PMID: 10335761]
[38]
Thi HT,Thi LP,Van TN,Minh PPT,Trong HN,Van TC,Huu SN,Minh TT,Huu ND,Van TH,Cam VT,Huyen ML,Hau KT,Thanh TN,Thi PH,Thuy LN,Gandolfi M,Satolli F,Feliciani C,Tirant M,Vojvodic A,Lotti T, The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience. Open access Macedonian journal of medical sciences. 2019 Jan 30;
[PubMed PMID: 30745975]
[39]
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M, European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum, World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul:69(7):868-87. doi: 10.1111/all.12313. Epub 2014 Apr 30
[PubMed PMID: 24785199]
[40]
Paakkari I, Cardiotoxicity of new antihistamines and cisapride. Toxicology letters. 2002 Feb 28;
[PubMed PMID: 12052668]
Level 3 (low-level) evidence
[41]
Greenwald PW,Farmer BM,O'Neill M,Essner RA,Flomenbaum NE, Increasing frequency and fatality of poison control center reported exposures involving medication and multiple substances: data from reports of the American Association of Poison Control Centers 1984-2013. Clinical toxicology (Philadelphia, Pa.). 2016 Aug;
[PubMed PMID: 27214065]
[42]
Skypala IJ,de Jong NW,Angier E,Gardner J,Kull I,Ryan D,Venter C,Vlieg-Boerstra BJ,Grimshaw K, Promoting and achieving excellence in the delivery of Integrated Allergy Care: the European Academy of Allergy
[PubMed PMID: 30151118]